Prostate cancer decisions — 2023

The Board has dismissed the appeals for restoration of a 100 percent rating for prostate cancer and TDIU prior to September 23, 2014, as well as service connection for depression, anxiety, bilateral hearing loss, and tinnitus due to lack of appeal after the Appellant withdrew her claims.

The Veteran's claim for service connection for a prostate disorder, claimed as prostate cancer, is remanded due to the need for an examination to determine if he has a current disability and whether it is related to his military service.

The Board denied service connection for prostate cancer residuals and erectile dysfunction, finding the evidence less likely as not to be related to in-service exposure to ionizing radiation.

The Board has remanded the cases for further development and to obtain additional medical opinions regarding service connection.

The Board has remanded the claims for prostate cancer, hypertension, erectile dysfunction, and a psychiatric disability due to herbicide agent exposure. The Veteran's assertions regarding his service and exposure are sufficient to trigger VA's duty to provide an examination.

The Board denied service connection for diabetes mellitus, type 2 and prostate cancer as secondary to in-service exposure to herbicide agents, including Agent Orange.

The Veteran's appeal is not ready for adjudication due to incomplete records, and the case is being remanded to obtain additional VA treatment records.

The Board has remanded the claims for diabetes mellitus type II, prostate cancer, and erectile dysfunction due to exposure at Camp Lejeune. The case will be returned for further development.

The Veteran's prostate cancer residuals are granted service connection on a presumptive basis due to exposure to burn pits during his Southwest Asia deployment. His erectile dysfunction is also granted as secondary to his service-connected prostate cancer.

The Veteran's death is being remanded due to the need for an opinion regarding whether his prostate cancer and/or bladder cancer were service-connected.

The Board has remanded the cases for further development and consideration, including obtaining service treatment records, determining if the Veteran was exposed to toxic substances while serving in the Navy, and providing a medical opinion regarding the etiology of the Veteran's prostate cancer.

The Board denied service connection for prostate cancer and erectile dysfunction, finding no evidence of herbicide exposure or direct service connection.

The Board has found that the Veteran's claims for prostate cancer, skin cancer, brain cancer, and erectile dysfunction are remanded due to insufficient information regarding exposure to toxins or asbestos. The VA will need to verify if the Veteran was exposed to these substances during his service aboard USS Sierra and US Naval Facility Eleuthera, Bahamas from 1968 to 1972.

The Veteran's diabetes mellitus, coronary artery disease, and prostate cancer residuals are granted as presumptively related to herbicide agent exposure under the PACT Act.,Service connection for peripheral neuropathy of the bilateral lower extremities is granted as secondary to now-service connected diabetes mellitus.

The Board has decided to remand the Veteran's claim for prostate cancer, including as due to asbestos exposure, due to insufficient development and examination. The AOJ must verify any asbestos exposure during service and schedule a VA examination.

The Veteran's hypertension, ischemic heart disease, prostate cancer, diabetes mellitus type II, and Parkinson's disease are all granted as service-connected due to herbicide exposure in Vietnam.,Special monthly compensation based on the need for regular aid and attendance is also granted.

The Board has decided to remand the case due to the need for further development and readjudication, specifically regarding whether the Veteran's fecal incontinence is secondary or aggravated by his radiation therapy for prostate cancer.

The Veteran's claims for increased ratings and service connection are remanded due to the need for updated examinations.

The Veteran's PTSD is currently rated at 50 percent from September 13, 2022. The criteria for a higher rating are not met.,The Veteran's residuals of prostate cancer are currently rated at 20 percent from September 15, 2022. The criteria for a higher rating are not met.

The Board has remanded the Veteran's claims for prostate and bladder disabilities, including those related to herbicide exposure during service. The case requires further development to obtain updated medical records and contact the Veteran for additional information.